Olaparib

With Over USD 4 Billion in Capital Investment, the Synthetic Lethality-based Drugs Market is Poised to Witness a Rapid Growth, Claims Roots Analysis

Retrieved on: 
Friday, August 16, 2019
Organic compounds, Chemical compounds, Heterocyclic compounds, Lactams, PARP inhibitors, RTT, Antineoplastic drugs, Genetics, Synthetic lethality, Targeted therapy, Olaparib, Rucaparib

The synthetic lethality approach enables the development of targeted therapies that are inherently able to select between normal and transformed cells.

Key Points: 
  • The synthetic lethality approach enables the development of targeted therapies that are inherently able to select between normal and transformed cells.
  • With four approved drugs, namely olaparib, rucaparib, talazoparib and niraparib, the synthetic lethality-based drugs pipeline has evolved significantly over the past few years.
  • Indications with more than eight drugs in different stages of development includeadvanced solid tumors, breast cancer, and ovarian cancer.
  • The USD 6.5 billion (by 2030) financial opportunity within the synthetic lethality market has been analyzed across the following segments:

With Over USD 4 Billion in Capital Investment, the Synthetic Lethality-based Drugs Market is Poised to Witness a Rapid Growth, Claims Roots Analysis

Retrieved on: 
Friday, August 16, 2019
Organic compounds, Chemical compounds, Heterocyclic compounds, Lactams, PARP inhibitors, RTT, Antineoplastic drugs, Genetics, Synthetic lethality, Targeted therapy, Olaparib, Rucaparib

The synthetic lethality approach enables the development of targeted therapies that are inherently able to select between normal and transformed cells.

Key Points: 
  • The synthetic lethality approach enables the development of targeted therapies that are inherently able to select between normal and transformed cells.
  • With four approved drugs, namely olaparib, rucaparib, talazoparib and niraparib, the synthetic lethality-based drugs pipeline has evolved significantly over the past few years.
  • Indications with more than eight drugs in different stages of development includeadvanced solid tumors, breast cancer, and ovarian cancer.
  • The USD 6.5 billion (by 2030) financial opportunity within the synthetic lethality market has been analyzed across the following segments:

Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer

Retrieved on: 
Wednesday, August 7, 2019
Cancer, RTT, Branches of biology, Organic compounds, Lactams, Breast cancer, MCRPC, Prostate cancer, Olaparib, BRCA mutation, Biomarker, PARP inhibitor

Myriad will file a supplementary Premarket Approval Application (sPMA) with the U.S. Food and Drug Administration (FDA) to authorize BRACAnalysis CDx as a companion diagnostic test for olaparib in mCRPC patients with germline BRCA mutations.

Key Points: 
  • Myriad will file a supplementary Premarket Approval Application (sPMA) with the U.S. Food and Drug Administration (FDA) to authorize BRACAnalysis CDx as a companion diagnostic test for olaparib in mCRPC patients with germline BRCA mutations.
  • The PROfound trial confirmed the potential benefits of using biomarkers to help guide care for men with metastatic castration-resistant prostate cancer, said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetics.
  • This study is another example of Myriads commitment to help our pharmaceutical partners achieve and deliver precision medicine for people with cancer.
  • It is estimated there are more than 170,000 men are diagnosed with prostate cancer each year.

LYNPARZA® (olaparib) Phase 3 PROfound Trial in HRR Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint

Retrieved on: 
Wednesday, August 7, 2019
General Health, Health, Pharmaceutical, Clinical trials, Organic compounds, Chemical compounds, Cancer, RTT, PARP inhibitors, Lactams, Prostate cancer, Olaparib, MCRPC, Ovarian cancer, Abiraterone acetate, Prostvac, PROfound, LYNPARZA® (olaparib), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Homologous Recombination Repair (HRR) Mutations, the AstraZeneca and Merck Strategic Oncology Collaboration, Merck

This is the only positive Phase 3 trial of any PARP inhibitor in metastatic castration-resistant prostate cancer, where the need for new, effective therapies is high.

Key Points: 
  • This is the only positive Phase 3 trial of any PARP inhibitor in metastatic castration-resistant prostate cancer, where the need for new, effective therapies is high.
  • The Phase 3 PROfound trial is another example of Merck and AstraZenecas shared commitment to improving long-term outcomes for people living with cancer.
  • The companies are also exploring additional trials in prostate cancer, including the ongoing Phase 3 PROpel trial, evaluating LYNPARZA as a first-line therapy in mCRPC, in combination with abiraterone.
  • Select patients with gBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on an FDA-approved companion diagnostic for LYNPARZA.

LYNPARZA® (Olaparib) Phase III Profound Trial in HRR* Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint

Retrieved on: 
Wednesday, August 7, 2019
Oncology, Health, Clinical trials, General Health, Pharmaceutical, Organic compounds, Chemical compounds, Amides, Prostate cancer, PARP inhibitors, Lactams, RTT, Olaparib, MCRPC, Abiraterone acetate, Draft:Adaptive therapy, PROfound, LYNPARZA® (olaparib), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Homologous Recombination Repair (HRR) Mutations, the AstraZeneca and Merck Strategic Oncology Collaboration, AstraZeneca in Oncology, AstraZeneca

This trial is the only positive Phase III trial of any PARP inhibitor in metastatic castration-resistant prostate cancer, where the need for new effective therapies is high.

Key Points: 
  • This trial is the only positive Phase III trial of any PARP inhibitor in metastatic castration-resistant prostate cancer, where the need for new effective therapies is high.
  • The Phase III PROfound trial is another example of Merck and AstraZenecas shared commitment to improving long-term outcomes for people living with cancer.
  • The companies are also exploring additional trials in prostate cancer, including the ongoing Phase III PROpel trial, evaluating LYNPARZA as a 1st-line therapy in mCRPC, in combination with abiraterone.
  • For first-line maintenance in advanced ovarian cancer and the metastatic breast cancer setting, physicians should select patients for therapy based on an FDA-approved companion diagnostic.

LYNPARZA® (olaparib) Phase 3 SOLO3 Trial Demonstrated a 72% Objective Response Rate in Patients with Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer Compared to 51% of Patients Receiving Chemotherapy

Retrieved on: 
Monday, June 3, 2019
Women, Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Research, Consumer, Science, Medicine, Clinical medicine, Cancer, Oncology, RTT, Cancer treatments, Lactams, PARP inhibitors, Ovarian cancer, Chemotherapy, Olaparib, Abagovomab

This is the fourth positive Phase 2 or Phase 3 trial in advanced ovarian cancer for LYNPARZA across multiple lines of therapy.

Key Points: 
  • This is the fourth positive Phase 2 or Phase 3 trial in advanced ovarian cancer for LYNPARZA across multiple lines of therapy.
  • It is approved in the U.S. as first-line maintenance treatment in BRCAm advanced ovarian cancer following response to platinum-based chemotherapy.
  • SOLO3 is a Phase 3 randomized, open-label, controlled, multi-center trial to evaluate the efficacy and safety of LYNPARZA tablets following two or more prior lines of chemotherapy.
  • Ovarian cancer is a leading cause of cancer death in women worldwide, with a five-year survival rate of 19%.

Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market 2019-2023 | 17% CAGR Projection over the Next Four Years | Technavio

Retrieved on: 
Monday, April 8, 2019
Seniors, Women, Health, Biotechnology, Oncology, Pharmaceutical, Consumer, Organic compounds, Chemical compounds, PARP, PARP inhibitors, Branches of biology, Programmed cell death, Lactams, Poly (ADP-ribose) polymerase, Olaparib

As a result, the global PARP inhibitors market is expected to witness significant growth during the forecast period.

Key Points: 
  • As a result, the global PARP inhibitors market is expected to witness significant growth during the forecast period.
  • This global PARP (poly ADP-ribose polymerase) inhibitors market 2019-2023 research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023.
  • The need to address the vast unmet needs will add significant value to the global PARP inhibitors market in the coming years.
  • Global PARP (poly ADP-ribose polymerase) inhibitors market: Segmentation analysis
    This research report on the PARP inhibitors market segments the market by indication (ovarian cancer, breast cancer, and others) and geography (Asia, Europe, North America, and ROW).

LYNPARZA® (olaparib) Reduced the Risk of Disease Progression or Death as 1st-Line Maintenance Treatment in Germline BRCA-Mutated Metastatic Pancreatic Cancer

Retrieved on: 
Tuesday, February 26, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Research, Science, Cancer, RTT, Medicine, Clinical medicine, Oncology, Hereditary cancers, Breast cancer, PARP inhibitors, Pancreatic cancer, Olaparib, BRCA mutation, Metástasis

Based on POLO, LYNPARZA becomes the first PARP inhibitor to demonstrate positive Phase III results beyond ovarian cancer and breast cancer.

Key Points: 
  • Based on POLO, LYNPARZA becomes the first PARP inhibitor to demonstrate positive Phase III results beyond ovarian cancer and breast cancer.
  • The clinically-meaningful results of this trial potentially support the value of testing for germline BRCA mutations in patients with metastatic pancreatic cancer.
  • The trial randomized 154 patients with gBRCAm metastatic pancreatic cancer whose disease had not progressed on 1st-line platinum-based chemotherapy.
  • Early diagnosis of pancreatic cancer is difficult, as often there are no symptoms until the disease has advanced.

LYNPARZA® (olaparib) Reduced the Risk of Disease Progression or Death as First-Line Maintenance Treatment in Germline BRCA-Mutated Metastatic Pancreatic Cancer

Retrieved on: 
Tuesday, February 26, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Chemistry, RTT, Cancer, PARP inhibitors, Organic chemistry, Lactams, Breast cancer, Olaparib, Pancreatic cancer, BRCA mutation, Talazoparib, Rucaparib

POLO is a randomized, double-blinded, placebo-controlled trial exploring the efficacy of LYNPARZA tablets as first-line maintenance monotherapy in patients with germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas (pancreatic cancer) whose disease has not progressed on platinum-based chemotherapy.

Key Points: 
  • POLO is a randomized, double-blinded, placebo-controlled trial exploring the efficacy of LYNPARZA tablets as first-line maintenance monotherapy in patients with germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas (pancreatic cancer) whose disease has not progressed on platinum-based chemotherapy.
  • Based on POLO, LYNPARZA becomes the first PARP inhibitor to demonstrate positive Phase 3 results beyond ovarian cancer and breast cancer.
  • The clinically-meaningful results of this trial potentially support the value of testing for germline BRCA mutations in patients with metastatic pancreatic cancer.
  • The trial randomized 154 patients with gBRCAm metastatic pancreatic cancer whose disease has not progressed on first-line platinum-based chemotherapy.

Carrick Therapeutics In-Licenses Targeted Ovarian Cancer Treatment From BTG and Appoints George Golumbeski as Chairman

Retrieved on: 
Thursday, October 11, 2018
Cancer, RTT, Medicine, Gynaecological cancer, Gynaecology, Oncology, Ovarian cancer, Targeted therapy, Olaparib, Clear-cell ovarian carcinoma

It was discovered by The Institute of Cancer Research, London, who led its earlier development with support from Cancer Research UK and BTG.

Key Points: 
  • It was discovered by The Institute of Cancer Research, London, who led its earlier development with support from Cancer Research UK and BTG.
  • There are approximately 240,000 new ovarian cancer patients per year worldwide[2] with 70% of patients presenting with advanced disease[3].
  • She added: "CT900, which is a targeted therapy, has already demonstrated clinical activity in platinum-resistant/refractory high-grade serous ovarian cancer.
  • Carrick also announced today that Dr. George Golumbeski has been appointed Chairman of the Board of Directors.